A look at the events that led up to the detention of South Korean President Yoon Suk Yeol
The long struggle to establish Martin Luther King Jr. Day
Two private lunar landers head toward the moon in a roundabout journey
Trump's Greenland bid stirs debate in China about what to do with Taiwan
TikTok preparing for U.S. shut-off on Sunday, The Information reports
Japan's Makino Milling requests changes to unsolicited bid from Nidec
As Los Angeles burns, Hollywood's Oscar season turns into a pledge drive
As fires ravage Los Angeles, Tiger Woods isn't sure what will happen with Riviera tournament
Antetokounmpo gets 50th career triple-double as Bucks win 130-115 to end Kings' 7-game win streak
(Reuters) - Goldman Sachs Asset Management said on Wednesday it had raised $650 million for a new fund that will invest in startups related to the life sciences sector.
The fund, West Street Life Sciences I, will specifically target early to mid-stage therapeutic companies with multi-asset portfolios as well as tools and diagnostics firms.
"Life sciences represents one of the most exciting areas in the private investing landscape, with advances in technology transforming healthcare at an unprecedented pace," said Marc Nachmann, global head of Asset & Wealth Management at Goldman Sachs.
Goldman said Life Sciences I has already committed about $90 million to five companies, including cancer drug maker Nested Therapeutics and precision medicine firm MOMA Therapeutics.
The company had raised about $4 billion for its infrastructure fund, West Street Infrastructure Partners IV, last year.
(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Krishna Chandra Eluri)
